Biomebank

Fecal Microbiota Transplantation Shows Safety and Tolerability in Six-Month Parkinson's Disease Pilot Study

- A pilot study of 12 Parkinson's disease patients demonstrated that six-month fecal microbiota transplantation (FMT) therapy is safe and well-tolerated, with 92% completing the full treatment course. - Patients showed significant improvement in quality of life scores at two months, with trends toward improvement in non-motor symptoms, though these benefits were not sustained at six months. - The study represents the first evaluation of extended FMT therapy in Parkinson's disease, establishing a foundation for larger randomized controlled trials to assess therapeutic efficacy.